ePrints

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

Lookup NU author(s): Emeritus Professor David Bates

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.

Publication metadata

Author(s): Carroll WM, Saida T, Kim HJ, Kira J, Kermode AG, Tsai CP, Fujihara K, Kusunoki S, Tanaka M, Kim KK, Bates D

Publication type: Article

Publication status: Published

Journal: Multiple Sclerosis Journal

Year: 2013

Volume: 19

Issue: 10

Pages: 1371-1380

Print publication date: 16/01/2013

ISSN (print): 1352-4585

ISSN (electronic): 1477-0970

Publisher: Sage

URL: http://dx.doi.org/10.1177/1352458512471092

DOI: 10.1177/1352458512471092

Altmetrics

Share